Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
20 Jun 2019 07:00 AM
RNS
Avacta and Selexis Partner to Develop Cell Line
19 Jun 2019 07:00 AM
RNS
Turner Pope Investor Evening
12 Jun 2019 07:00 AM
RNS
Avacta's CSO to Present at Major US Conference
10 Jun 2019 07:00 AM
RNS
Avacta hits Clinical Candidate Selection Milestone
03 Jun 2019 07:00 AM
RNS
TMAC Programme Accelerates
23 Apr 2019 03:48 PM
RNS
Issue of Equity
12 Apr 2019 02:46 PM
RNS
Holding(s) in Company
09 Apr 2019 07:00 AM
RNS
Interim Results
08 Mar 2019 12:14 PM
RNS
Issue of Equity
06 Feb 2019 12:27 PM
EQS
Avacta (AVCT): A second wake-up call for the ma...
04 Feb 2019 07:00 AM
RNS
Moderna Exercises Exclusive Product License Option
28 Jan 2019 07:00 AM
RNS
Director Appointment
21 Jan 2019 03:40 PM
RNS
Result of Annual General Meeting
21 Jan 2019 07:00 AM
RNS
AGM Business Update and Notice of Results
18 Jan 2019 05:08 PM
RNS
Share Incentive Plan/Issue of Equity
18 Jan 2019 10:00 AM
RNS
Change of accounting reference date
09 Jan 2019 11:06 AM
RNS
Holding(s) in Company
07 Jan 2019 02:50 PM
RNS
Director/PDMR Shareholdings
03 Jan 2019 08:56 AM
RNS
Holding(s) in Company
02 Jan 2019 07:00 AM
RNS
Director/PDMR Shareholding
21 Dec 2018 01:41 PM
RNS
Holding(s) in Company
19 Dec 2018 03:32 PM
RNS
Holding(s) in Company
17 Dec 2018 07:00 AM
RNS
Avacta London Science Day
12 Dec 2018 12:50 PM
RNS
Holding(s) in Company
12 Dec 2018 12:44 PM
RNS
Holding(s) in Company
12 Dec 2018 07:00 AM
RNS
Appointment of Chief Medical Officer
11 Dec 2018 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
10 Dec 2018 02:05 PM
RNS
Second Price Monitoring Extn
10 Dec 2018 02:00 PM
RNS
Price Monitoring Extension
10 Dec 2018 07:30 AM
EQS
Avacta (AVCT): Wake-up call for the market
10 Dec 2018 07:00 AM
RNS
Development Partnership with LG Chem Life Sciences
12 Nov 2018 07:00 AM
RNS
Avacta to Present at Major European Conference
11 Oct 2018 07:00 AM
RNS
Avacta's CTO to Present at Major US Conference
10 Oct 2018 07:00 AM
RNS
Avacta agrees Affimer reagent licensing deal
02 Oct 2018 07:00 AM
RNS
Preliminary Results
21 Sep 2018 07:00 AM
RNS
Investor Meeting and Presentation
05 Sep 2018 07:15 AM
EQS
Avacta (AVCT): Capital increase for further dev...
05 Sep 2018 07:00 AM
RNS
Notice of Results
31 Aug 2018 09:55 AM
RNS
Holding(s) in Company
23 Aug 2018 05:07 PM
RNS
Holding(s) in Company
23 Aug 2018 05:06 PM
RNS
Holding(s) in Company
23 Aug 2018 11:21 AM
RNS
Holding(s) in Company
22 Aug 2018 02:23 PM
RNS
Holding(s) in Company
22 Aug 2018 09:20 AM
RNS
Holding(s) in Company
17 Aug 2018 11:30 AM
RNS
Result of General Meeting
06 Aug 2018 04:24 PM
RNS
Holding(s) in Company
30 Jul 2018 06:06 PM
RNS
Results of Placing and Subscription
30 Jul 2018 11:41 AM
RNS
Proposed Placing and Subscription to raise £11.4m
30 Jul 2018 10:35 AM
EQS
Avacta (AVCT): Ground-breaking new drug conjuga...
24 Jul 2018 07:00 AM
RNS
Major Therapeutics Co-development Partnership

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100

Latest directors dealings